NEMBO-02 study indicates rapid cSDH resorption and pain-free treatments with NeoCast liquid embolic agent featuring Arsenal Medical
Arsenal Medical has announced late-breaking data from the EMBO-02 clinical study evaluating NeoCast—a next-generation, shear-responsive liquid embolic agent—in the treatment of patients with chronic subdural haematoma (cSDH) via middle meningeal artery embolisation (MMAe). Research presented across multiple sessions at the Society of NeuroInterventional Surgery (SNIS) annual meeting (14–18 July, Nashville, USA) showed that all patients met primary safety and feasibility endpoints, in addition to demonstrating that NeoCast can be administered painlessly and leads to rapid haematoma resorption.
A total of 15 patients with cSDH have been enrolled in EMBO-02 across three sites in Australia. The initial cohort of 10 patients allowed either general anaesthesia or conscious sedation, while the second cohort of five patients specified the use of conscious sedation, according to Arsenal Medical.
Highlights from the study’s results to date include 87% of patients undergoing embolisation without adjunctive surgery; 100% target vessel occlusion alongside no non-target embolisations; and no NeoCast-related adverse events.
